Sphera Funds Management LTD. Has $8.14 Million Stake in Pharvaris (NASDAQ:PHVS)

Sphera Funds Management LTD. boosted its holdings in shares of Pharvaris (NASDAQ:PHVS) by 8.9% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 439,292 shares of the company’s stock after purchasing an additional 36,027 shares during the period. Pharvaris accounts for approximately 1.3% of Sphera Funds Management LTD.’s holdings, making the stock its 24th largest holding. Sphera Funds Management LTD.’s holdings in Pharvaris were worth $8,136,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in PHVS. Novo Holdings A S increased its stake in shares of Pharvaris by 47.7% in the 2nd quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after buying an additional 556,970 shares during the period. Deerfield Management Company L.P. Series C increased its stake in shares of Pharvaris by 31.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after buying an additional 335,687 shares during the period. Patient Square Capital LP acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $4,488,000. State Street Corp acquired a new stake in shares of Pharvaris in the 3rd quarter valued at $1,000,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pharvaris during the third quarter worth $906,000.

Analyst Ratings Changes

Separately, Oppenheimer lifted their price objective on Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research note on Friday, September 6th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.60.

Pharvaris Trading Up 1.1 %

PHVS stock opened at $20.00 on Thursday. The business’s 50-day moving average price is $21.09 and its two-hundred day moving average price is $19.29. Pharvaris has a 1-year low of $15.37 and a 1-year high of $33.00.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.